229 related articles for article (PubMed ID: 21371545)
1. In vitro and in vivo anti-tumor activities of a gemcitabine derivative carried by nanoparticles.
Sloat BR; Sandoval MA; Li D; Chung WG; Lansakara-P DS; Proteau PJ; Kiguchi K; DiGiovanni J; Cui Z
Int J Pharm; 2011 May; 409(1-2):278-88. PubMed ID: 21371545
[TBL] [Abstract][Full Text] [Related]
2. Preparation of intravenous injection nanoformulation of VESylated gemcitabine by co-assembly with TPGS and its anti-tumor activity in pancreatic tumor-bearing mice.
Xu Y; Meng H; Du F; Lu W; Liu S; Huang J; Yu J
Int J Pharm; 2015 Nov; 495(2):792-7. PubMed ID: 26410754
[TBL] [Abstract][Full Text] [Related]
3. EGFR-targeted stearoyl gemcitabine nanoparticles show enhanced anti-tumor activity.
Sandoval MA; Sloat BR; Lansakara-P DS; Kumar A; Rodriguez BL; Kiguchi K; Digiovanni J; Cui Z
J Control Release; 2012 Jan; 157(2):287-96. PubMed ID: 21871505
[TBL] [Abstract][Full Text] [Related]
4. PEGylated liposomal Gemcitabine: insights into a potential breast cancer therapeutic.
Papa AL; Sidiqui A; Balasubramanian SU; Sarangi S; Luchette M; Sengupta S; Harfouche R
Cell Oncol (Dordr); 2013 Dec; 36(6):449-57. PubMed ID: 24081907
[TBL] [Abstract][Full Text] [Related]
5. Diels Alder-mediated release of gemcitabine from hybrid nanoparticles for enhanced pancreatic cancer therapy.
Oluwasanmi A; Al-Shakarchi W; Manzur A; Aldebasi MH; Elsini RS; Albusair MK; Haxton KJ; Curtis ADM; Hoskins C
J Control Release; 2017 Nov; 266():355-364. PubMed ID: 28943195
[TBL] [Abstract][Full Text] [Related]
6. Magnetic poly epsilon-caprolactone nanoparticles containing Fe3O4 and gemcitabine enhance anti-tumor effect in pancreatic cancer xenograft mouse model.
Gang J; Park SB; Hyung W; Choi EH; Wen J; Kim HS; Shul YG; Haam S; Song SY
J Drug Target; 2007 Jul; 15(6):445-53. PubMed ID: 17613663
[TBL] [Abstract][Full Text] [Related]
7. PEGylation of Carbonate Apatite Nanoparticles Prevents Opsonin Binding and Enhances Tumor Accumulation of Gemcitabine.
Mozar FS; Chowdhury EH
J Pharm Sci; 2018 Sep; 107(9):2497-2508. PubMed ID: 29883662
[TBL] [Abstract][Full Text] [Related]
8. Polyisoprenoyl gemcitabine conjugates self assemble as nanoparticles, useful for cancer therapy.
Maksimenko A; Mougin J; Mura S; Sliwinski E; Lepeltier E; Bourgaux C; Lepêtre S; Zouhiri F; Desmaële D; Couvreur P
Cancer Lett; 2013 Jul; 334(2):346-53. PubMed ID: 22935679
[TBL] [Abstract][Full Text] [Related]
9. Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy.
Camp ER; Wang C; Little EC; Watson PM; Pirollo KF; Rait A; Cole DJ; Chang EH; Watson DK
Cancer Gene Ther; 2013 Apr; 20(4):222-8. PubMed ID: 23470564
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine-based therapy for pancreatic cancer using the squalenoyl nucleoside monophosphate nanoassemblies.
Maksimenko A; Caron J; Mougin J; Desmaële D; Couvreur P
Int J Pharm; 2015 Mar; 482(1-2):38-46. PubMed ID: 25448549
[TBL] [Abstract][Full Text] [Related]
11. Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer.
Réjiba S; Reddy LH; Bigand C; Parmentier C; Couvreur P; Hajri A
Nanomedicine; 2011 Dec; 7(6):841-9. PubMed ID: 21419876
[TBL] [Abstract][Full Text] [Related]
12. Lysosomal delivery of a lipophilic gemcitabine prodrug using novel acid-sensitive micelles improved its antitumor activity.
Zhu S; Lansakara-P DS; Li X; Cui Z
Bioconjug Chem; 2012 May; 23(5):966-80. PubMed ID: 22471294
[TBL] [Abstract][Full Text] [Related]
13. Site specific/targeted delivery of gemcitabine through anisamide anchored chitosan/poly ethylene glycol nanoparticles: an improved understanding of lung cancer therapeutic intervention.
Garg NK; Dwivedi P; Campbell C; Tyagi RK
Eur J Pharm Sci; 2012 Dec; 47(5):1006-14. PubMed ID: 23041219
[TBL] [Abstract][Full Text] [Related]
14. Just getting into cells is not enough: mechanisms underlying 4-(N)-stearoyl gemcitabine solid lipid nanoparticle's ability to overcome gemcitabine resistance caused by RRM1 overexpression.
Wonganan P; Lansakara-P DS; Zhu S; Holzer M; Sandoval MA; Warthaka M; Cui Z
J Control Release; 2013 Jul; 169(1-2):17-27. PubMed ID: 23570983
[TBL] [Abstract][Full Text] [Related]
15. Preparation, physicochemical characterization and cytotoxicity in vitro of gemcitabine-loaded PEG-PDLLA nanovesicles.
Jia L; Zheng JJ; Jiang SM; Huang KH
World J Gastroenterol; 2010 Feb; 16(8):1008-13. PubMed ID: 20180242
[TBL] [Abstract][Full Text] [Related]
16. pH-Sensitive Nanoparticles Composed Solely of Membrane-Disruptive Macromolecules for Treating Pancreatic Cancer.
Fan F; Jin L; Yang L
ACS Appl Mater Interfaces; 2021 Mar; 13(11):12824-12835. PubMed ID: 33689289
[TBL] [Abstract][Full Text] [Related]
17. Temperature-sensitive magnetic drug carriers for concurrent gemcitabine chemohyperthermia.
Kim DH; Guo Y; Zhang Z; Procissi D; Nicolai J; Omary RA; Larson AC
Adv Healthc Mater; 2014 May; 3(5):714-24. PubMed ID: 24574255
[TBL] [Abstract][Full Text] [Related]
18. Folate-Conjugated pH-Responsive Nanocarrier Designed for Active Tumor Targeting and Controlled Release of Gemcitabine.
Pourjavadi A; Tehrani ZM; Moghanaki AA
Pharm Res; 2016 Feb; 33(2):417-32. PubMed ID: 26438181
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of gemcitabine hydrochloride loaded lipid polymer hybrid nanoparticles (LPHNs): In vitro and in vivo.
Yalcin TE; Ilbasmis-Tamer S; Takka S
Int J Pharm; 2020 Apr; 580():119246. PubMed ID: 32205141
[TBL] [Abstract][Full Text] [Related]
20. Long-circulatory nanoparticles for gemcitabine delivery: Development and investigation of pharmacokinetics and in-vivo anticancer efficacy.
Khare V; Singh A; Mahajan G; Alam N; Kour S; Gupta M; Kumar A; Singh G; Singh SK; Saxena AK; Mondhe DM; Gupta PN
Eur J Pharm Sci; 2016 Sep; 92():183-93. PubMed ID: 27404580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
